Regional efficacy assessment in multiregional clinical development.
It is common in multiregional clinical development that data from a global trial and a local trial (in a target country) together will be used to support local filing in the target country. This approach is considered efficient drug development both globally and in the target country. However, it remains a challenge how to combine global trial data and local trial data toward local filing. To address this challenge, we propose an "interpretation-centric" evaluation criterion based on a weighted estimator that weights data from the target country and outside of the target country. This approach provides an unbiased estimate of a global treatment effect with appropriate representation of the target country patient population, where the "appropriate representation" is the desired proportion of the target country participants in a global trial and is measured by the weight parameter. This natural interpretation can facilitate drug development discussion with local regulatory agencies. Sample size of the local trial can be determined using the proposed weighted estimator. Approaches for weight determination are also discussed.
a Data and Statistical Sciences, AbbVie Inc. , North Chicago , Illinois , USA.
Yijie
Y
Zhou
a Data and Statistical Sciences, AbbVie Inc. , North Chicago , Illinois , USA.
Lu
L
Cui
a Data and Statistical Sciences, AbbVie Inc. , North Chicago , Illinois , USA.
Bo
B
Yang
a Data and Statistical Sciences, AbbVie Inc. , North Chicago , Illinois , USA.
Lanju
L
Zhang
a Data and Statistical Sciences, AbbVie Inc. , North Chicago , Illinois , USA.
Frank
F
Shen
D002986:Clinical Trials as Topic; D003627:Data Interpretation, Statistical; D015195:Drug Design; D006801:Humans; D015337:Multicenter Studies as Topic; D018401:Sample Size
Global trial; local trial; multiregional clinical development; target country; weighted estimator